3i Nordic plc Company Profile

16:47 EDT 23rd March 2018 | BioPortfolio

3i Group plc is a leading international venture capital company. 3i invests in ambitious, growing businesses across the world through 35 investment teams in Europe, Asia Pacific and the USA. It invests in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on businesses with high growth potential and strong management.


Niels Juels Gade 5


Phone: +45 33 38 23 36
Fax: +45 33 38 21 83

News Articles [96 Associated News Articles listed on BioPortfolio]

Nordic Nanovector to Present at Carnegie Nordic Healthcare Day

OSLO, Norway, Dec. 4, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting at the Carnegie Nordic Healthcare day on 5th of December 2017 in New York...

Bavarian Nordic A/S: Bavarian Nordic to Host Full Year 2017 Results Conference Call

COPENHAGEN, Denmark - March 7, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2017 annual report on Monday, March 12, 2018. The management of Bavarian Nordic will host a conf...

Nordic Nanovector ASA - Allocation of PSUs

OSLO, Norway, Jan. 29,2018 /PRNewswire/ -- The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 29th of January 2018 decided to grant 216 550 Performance S...

Bavarian Nordic A/S: Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine

Award of approximately USD 37 million will support clinical work required for product approval COPENHAGEN, Denmark, November 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today ...

Nordic presents new Phase l/ll data of Betalutin

Nordic Nanovector has unveiled updated results from its LYMRIT 37-01 Phase l/ll clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) to treat patients...Read More... The post Nordic presents new...

Bavarian Nordic A/S: Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen

COPENHAGEN, Denmark, January 31, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that Ole Larsen, Executive Vice President and Chief Financial Officer will depart from the Compa...

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint...

Nordic project takes ‘manufacturing-on-demand’ approach to future drugs

Nordic Universities will investigate 3D printing, electrospraying, and microfluidics in an industry supported collaboration aimed at revolutionising production in an age of personalised medicine.

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Fareston [GTx, Inc.]

These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.FARESTON® (toremifene citrate) 60 mg Tablets oral ...

Comtan [Cardinal Health]

C OMTAN (entacapone) Tablets Rx only Prescribing Information

Comtan [Novartis Pharmaceuticals Corporation]

COMTAN (entacapone) Tablets

Stalevo [Novartis Pharmaceuticals Corporation]

Stalevo® 50 Stalevo® 75 Stalevo® 100 Stalevo® 125 Stalevo® 150 Stalevo® 200 (carbidopa, levodopa and entacapone) Tablets

PubMed Articles [40 Associated PubMed Articles listed on BioPortfolio]

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.

In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among p...

Encouraging effects of a short-term, adapted Nordic diet intervention on skin microvascular function and skin oxygen tension in younger and older adults.

The microvascular benefits of regional diets appear in the literature; however, little is known about Nordic-type diets. We investigated the effects of a short-term, adapted, Nordic diet on microvascu...

Dermatological moulage collections in the Nordic countries.

The art of producing and acquiring dermatological wax models, moulages, flourished all over Europe in the beginning of the twentieth century, whereas very little is known about the existence of moulag...

Obstetric and neonatal outcome in women aged 50 years and up: A collaborative, Nordic population-based study.

Childbearing at extremely advanced maternal age is a globally increasing trend, but only a few studies have described the outcomes of these pregnancies. The aim of this study was to describe the occur...

Recent evolution of 129I levels in the Nordic Seas and the North Atlantic Ocean.

Most of the anthropogenic radionuclide 129I released to the marine environment from the nuclear fuel reprocessing plants (NFRP) at Sellafield (England) and La Hague (France) is transported to the Arct...

Clinical Trials [46 Associated Clinical Trials listed on BioPortfolio]

Nordic Walking and Chronic Low Back Pain

This is a randimized clinical trial comparing the effect of supervised Nordic walking versus unsupervised Nordic walking versus advice to stay active

Healthy Nordic Foods to Prevent Cardiometabolic Risk in Obese Subjects

This project will examine whether long-term consumption of healthy Nordic foods can maintain a healthy weight also after weight loss, and decrease abdominal fat accumulation and cardiometa...

Eisenmenger Syndrome in the Nordic Countries

This is a historical cohort study with retrospective collection of data comprising all Nordic patient's diagnosed with Eisenmengers syndrome in the period 1977 through 2011. The goal is to...

WS®1442 in Slightly Overweight Subjects

The purpose of this study is to test: 1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²) 2. Pharmacodynamic effect of WS® ...

Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4

Hyperphosphatemia is a severe complication to chronic kidney disease (CKD) and is associated with increased risk of vascular calcification, cardiovascular morbidity and mortality. Early di...

Companies [44 Associated Companies listed on BioPortfolio]

Bavarian Nordic

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. Natio...

Nordic Nanovector

Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel inno...

CapMan Plc

CapMan is one of the leading private equity investors in the Nordic countries and manages Nordic funds with approximately €2.3 billion in total capital. CapMan's operations are divided into two busi...

Bavarian Nordic Research Institute A/S

Bavarian Nordic is a commercially viable international biopharmaceutical company through:Biopharmaceutical innovations Novel prophylactic and therapeutic approaches Development, production, testing an...

Nordic Bioscience Diagnostics A/S

Nordic Bioscience and its employees are committed to the development of therapeutic compounds and diagnostic products for improved management of patients suffering from diseases affecting bone and car...

More Information about "3i Nordic plc" on BioPortfolio

We have published hundreds of 3i Nordic plc news stories on BioPortfolio along with dozens of 3i Nordic plc Clinical Trials and PubMed Articles about 3i Nordic plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 3i Nordic plc Companies in our database. You can also find out about relevant 3i Nordic plc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record